Biofrontera (NASDAQ:BFRI – Get Free Report) and Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.
Insider and Institutional Ownership
10.1% of Biofrontera shares are held by institutional investors. 0.2% of Biofrontera shares are held by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Biofrontera has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 0 | 0 | 1 | 0 | 3.00 |
| Amicus Therapeutics | 0 | 2 | 7 | 0 | 2.78 |
Biofrontera presently has a consensus price target of $7.00, suggesting a potential upside of 604.08%. Amicus Therapeutics has a consensus price target of $16.88, suggesting a potential upside of 70.63%. Given Biofrontera’s stronger consensus rating and higher probable upside, analysts clearly believe Biofrontera is more favorable than Amicus Therapeutics.
Valuation and Earnings
This table compares Biofrontera and Amicus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $35.36 million | 0.22 | -$20.13 million | ($2.26) | -0.44 |
| Amicus Therapeutics | $493.67 million | 5.99 | -$151.58 million | ($0.34) | -29.09 |
Biofrontera has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biofrontera and Amicus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -36.31% | -565.73% | -96.64% |
| Amicus Therapeutics | -21.21% | -15.97% | -3.17% |
Summary
Amicus Therapeutics beats Biofrontera on 9 of the 14 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
